Clinical trials: Immunotherapy
- Condition Immunotherapy
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Perennial Allergic Rhinitis With Seasonal Variation
The Efficacy & Safety of the UAS Immunotherapy Protocol
Hypothesis: The UAS Immunotherapy protocol is efficacious and at least as efficacious as protocols described in the Allergy literature.
- Trial name
- NCT01699659
- Testing
- allergen immunotherapy
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- United Allergy Services
Herpes Simplex
A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
The purpose of this first-time-in-human (FTiH) study is to evaluate the reactogenicity, safety, immune response, and efficacy of an investigational herpes simplex virus (HSV)-targeted immunotherapy (TI).
- Trial name
- NCT05298254
- Testing
- Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3
- Where
- 30 sites in United States, Australia and 6 more
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HSV-2
A Safety Study to Assess a DNA Vaccine Administered by Particle Mediated Delivery to the Skin in Healthy Subjects
The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing.
- Trial name
- NCT00310271
- Testing
- pPJV7630 with pPJV2012 administered by PMED
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- PowderMed
Type I Hypersensitivity
Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen
Safety and tolerability of different dose combinations of MPL and grass pollen allergen and to identify the highest combinations of MPL and grass pollen allergen which is safe.
- Trial name
- NCT00241410
- Testing
- OralvacB2MPL
- Where
- Germany
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Allergy Therapeutics
Whooping Cough
Viaskin Pertussis Vaccine Trial
The study is a Phase I, first in human, monocenter study, aiming at assessing the safety and immunogenicity of a genetically detoxified pertussis toxin (PT) when administered via the cutaneous route with Viaskin patches to…
- Trial name
- NCT03035370
- Testing
- Viaskin PT 25 mcg, Viaskin PT 50 mcg, Boostrix™
- Where
- Switzerland
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- DBV Technologies
Cat Allergy
Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis. Cat-PAD is a novel, synthetic, allergen derived peptide desensitising vaccine currently being developed for…
- Trial name
- NCT01383603
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Circassia Limited
Melanoma, Healthy Volunteers
Polish Microbiome Map
Knowledge about the correlations between the composition of the gut microbiome and a wide range of diseases has substantially increased in recent years.
- Conditions
- Melanoma, Healthy Volunteers, Microbiome, Metagenome
- Trial name
- NCT04169867
- Testing
- Collection of stool samples
- Where
- Poland
- Volunteers
- 1,160 people, healthy volunteers welcome
- Sponsor
- Ardigen
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Migraine
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants
This first in-human (FIH) study of UB-313, an anti-calcitonin gene-related peptide based immunotherapeutic candidate, is designed to assess the safety, tolerability, and immunogenicity of 4 selected UB-313 dose regimens in…
- Trial name
- NCT05477095
- Testing
- UB-313
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vaxxinity, Inc.
Breastcancer
Immunotherapy Vaccine and Herceptin in Breast Cancer
The purpose of this trial is to determine if combination immunotherapy with HER2/neu GP2 peptide + GM-CSF vaccine and trastuzumab is safe and immunologically effective in treatment of patients with HER2/neu over-expressing breast…
- Trial name
- NCT03014076
- Testing
- GP2 peptide + GM-CSF vaccine plus trastuzumab, Trastuzumab
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Cancer Insight, LLC
Cat Allergy
Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis. Cat-PAD is a novel synthetic, allergen derived peptide desensitizing vaccine currently being developed for the…
- Trial name
- NCT01383590
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Circassia Limited
Allergic Rhinoconjunctivitis, Healthy Volunteers
Evaluation of the Utility of an EEC for Assessing Efficacy of SIT in Pivotal Clinical Trials
The study will explore how allergy symptoms experienced during the grass pollen season compare to symptoms experienced in the Environmental Exposure Chamber (EEC). There are 2 treatments in this study.
- Trial name
- NCT02297490
- Testing
- Allergovit 6-grasses
- Where
- Canada
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Allergopharma GmbH & Co. KG
Allergic Rhinoconjunctivitis
A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021)
This study will gather information on allergic rhinoconjunctivitis from surveys completed by adults and children.
- Trial name
- AIRS (NCT01535118)
- Volunteers
- 2,765 people, healthy volunteers welcome
- Sponsor
- ALK-Abelló A/S
Endometrial Carcinoma, Cervix Carcinoma
GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab
The aim of this study is to investigate the safety and the clinical activities of NP137 when combined with pembrolizumab and/or chemotherapies in patients with advanced/metastatic gynecological cancers (2 types: endometrial…
- Trial name
- GYNET (NCT04652076)
- Testing
- NP137, Pembrolizumab, Paclitaxel
- Where
- 15 sites in France
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- NETRIS Pharma
Endometriosis
Open Label Immunotherapy of Endometriosis
Endometriosis is a chronic gynecological disease characterized by sustained painful symptoms that are responsible for a decline in the quality of life of sufferers.
- Trial name
- NCT03340324
- Testing
- V-Endo
- Where
- Mongolia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Immunitor LLC
Stress
Natural Modulators of Immune Function and Mood
The objective of this proposal is to recruit 20 healthy subjects per ingredient arm (5 arms x 20 subjects; N= 120 total) to participate in a research study investigating the effects of dietary supplementation for one-month with…
- Trial name
- NCT05508529
- Testing
- Chaga Mushroom, Algae Extract, Black Cumin Seed Oil
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- 3 Waves Wellness
Type I Hypersensitivity
Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)
The safety and tolerability of tyrosine adsorbed ragweed pollen allergoid with monophosphoryl lipid A (MPL) was planned to be evaluated.
- Trial name
- NCT00109759
- Testing
- RagweedMATAMPL
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Allergy Therapeutics
Healthy Donors
Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)
The first objective of the project consists in the preclinical validation of new possible molecular targets associated with intratumoral T regulatory cells.
- Trial name
- Immuno-ab (NCT06842407)
- Where
- Italy
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Checkmab S.r.l.
Non Small Cell Lung Cancer
Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC
Subjects will be eligible for this study if they are about to start on a drug called nivolumab for lung cancer. Some patients' cancers respond to nivolumab but a majority of patients do not.
- Trial name
- NO3DEXPL (NCT03371992)
- Testing
- Nivolumab, 3D-EX, Evaluation of Response by RECIST
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Nilogen Oncosystems
Herpes Simplex
A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunotherapy Against HSV in Healthy Japanese Participants Aged 18-40 Years
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of 2 formulations of Herpes Simplex Virus (HSV)-Targeted Immunotherapy (HSVTI) in HSV-2 seronegative ethnic Japanese adults aged 18-40 years.
- Trial name
- TH HSV REC-004 (NCT05989672)
- Testing
- HSVTI Formulation 1, HSVTI Formulation 2
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline